This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva
Company News For Aug 12, 2019
by Zacks Equity Research
Companies In The News Are: UBER,AMGN,NWSA,DXC
Top Ranked Income Stocks to Buy for August 12th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, August 12th.
Top Analyst Reports: Amgen, Uber, Mondelez & More
by Kalyan Nandy
Today's Research Daily features updated research reports on 16 major stocks, including Amgen (AMGN), Uber (UBER) and Mondelez (MDLZ).
Puma (PBYI) Q2 Earnings Miss, Nerlynx Sales Rise, Stock Up
by Zacks Equity Research
Puma Biotech (PBYI) incurs wider loss in Q2. Sales of Nerlynx improve from first-quarter levels. Stock rises 23%.
Radius (RDUS) Q2 Earnings Beat Estimates, Tymlos Sales Solid
by Zacks Equity Research
Radius (RDUS) reports a narrower-then-expected loss and beats sales estimates in the second quarter of 2019.
Intercept (ICPT) Q2 Earnings & Sales Beat, NASH in Focus
by Zacks Equity Research
Intercept (ICPT) posts a narrower-than-expected loss in Q2 and surpasses sales estimates.
Teva (TEVA) Q2 Earnings, Sales Top Estimates, CFO Steps Down
by Zacks Equity Research
Teva Pharmaceutical (TEVA) posts better-than-expected results. However, earnings and sales decline year over year.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Biotech ETFs in Focus on Impressive Q2 Earnings Results
by Sweta Jaiswal, FRM
Let's take a look at some ETFs with wide exposure to a few biotechnological companies which released solid Q2 earnings results recently.
Allergan (AGN) Q2 Earnings & Sales Top, '19 Sales View Up
by Zacks Equity Research
Botox, Juvederm fillers, Vraylar and Ozurdex drive Allergan's (AGN) second-quarter sales, making up for loss of exclusivity on some brands and lower sales of Restasis and textured breast implants.
Is Amgen (AMGN) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Biotech Stock Roundup: Celgene, Amgen, Gilead Impress in Q2, Other Pipeline Updates
by Zacks Equity Research
Impressive second-quarter results by most biotech bigwigs are the key highlights of the week. Most companies also increase their annual guidance.
Ligand (LGND) Stock Down Despite Q2 Earnings & Sales Beat
by Zacks Equity Research
Ligand (LGND) reports better-than-expected second-quarter 2019 results and maintains view for the full year.
Amgen (AMGN) Q2 Earnings & Sales Beat, New Drugs Shine
by Zacks Equity Research
Amgen (AMGN) beats estimates for earnings and sales in the second quarter. Higher demand for new growth drivers was offset by the erosion of mature brands from brand/biosimilar competition.
Amgen (AMGN) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Amgen (AMGN) delivered earnings and revenue surprises of 10.89% and 3.43%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Lilly (LLY) Q2 Earnings Beat, New Drugs Drive Sales, Stock Up
by Zacks Equity Research
Eli Lilly's (LLY) Q2 earnings beat estimates while sales miss. New drugs drive sales despite generic competition to key drug Cialis.
Sanofi (SNY) Q2 Earnings Top, Dupixent Shines, EPS View Up
by Zacks Equity Research
Sanofi (SNY) beats estimates for second-quarter earnings. Key immunology drug Dupixent drives sales. The company ups its earnings growth expectations for the year.
Why Amgen (AMGN) Might Surprise This Earnings Season
by Zacks Equity Research
Amgen (AMGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
What's in the Cards for Pfizer (PFE) This Earnings Season?
by Zacks Equity Research
While Pfizer's (PFE) key drugs like Ibrance and Xeljanz are likely to drive Q2 sales, genericization of some older drugs will hurt the same.
AbbVie (ABBV) Beats on Q2 Earnings & Sales, Raises EPS View
by Zacks Equity Research
AbbVie (ABBV) beats second-quarter estimates for both earnings and revenues. Biosimilar competition impacts Humira sales in ex-U.S. markets. Growth in Imbruvica sales offsets Humira decline.
Can Newer Drugs Help Amgen (AMGN) Beat on Earnings in Q2?
by Zacks Equity Research
While Amgen's (AMGN) growth drugs like Prolia & Xgeva may do well, biosimilar competition and slowdown in sales of mature products are likely to put pressure on second-quarter sales.
5 Drug/Biotech Stocks Set to Beat Earnings Estimates in Q2
by Zacks Equity Research
We take a look at the overall drug/biotech sector's performance and five stocks that are poised to beat on earnings in the second quarter of 2019.
Roche (RHHBY) 1H19 Earnings & Sales Up Y/Y, View Raised
by Zacks Equity Research
Roche's (RHHBY) performance in the first half of 2019 is driven by solid strength in new drugs, which more than offset competition from biosimilars.
Is a Beat in the Cards for Celgene's (CELG) Q2 Earnings?
by Zacks Equity Research
Investors are looking forward to Revlimid's performance and updates on the acquisition by Bristol-Myers, when Celgene Corporation (CELG) reports Q2 results.
Amgen (AMGN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Amgen (AMGN) closed at $176.01, marking a +0.07% move from the previous day.